Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  International Cancer Conference Journal

• Publication date

  2016-08-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13691-016-0260-zPMID 31149457PMCID PMC6498329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

  2015cited by this paper
• Advances in targeted therapy for unresectable melanoma: new drugs and combinations.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.

  2015cited by this paper
• The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

  2014cited by this paper
• Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib

  2014cited by this paper
• Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

  2014cited by this paper
• Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

  2013cited by this paper
• Severe radiotherapy-induced extracutaneous toxicity under vemurafenib.

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

  2011cited by this paper
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

  2006cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.

  1999cited by this paper
• The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study.

  1986cited by this paper

• ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

  2026cites this paper
• Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

  2018cites this paper